Background Androgen deprivation therapy (ADT) is foundational in the management of
advanced prostate cancer (PCa) and has benefitted from a recent explosion in scientific …

Ferroptosis was first coined in 2012 to describe the form of regulated cell death (RCD)
characterized by iron‐dependent lipid peroxidation. To date, ferroptosis has been implicated …

Abstract Treatment with androgen receptor pathway inhibitors (ARPIs) in prostate cancer
leads to the emergence of resistant tumors characterized by lineage plasticity and …

Drug resistance is the main obstacle in the improvement of chemotherapeutic efficacy in
glioblastoma. Previously, we showed that dehydroepiandrosterone (DHEA), one kind of …

In the past two decades, we have witnessed the discovery and development of many potent
and efficacious proteolysis-targeting chimera (PROTAC) degraders, with several in phase I/II …

The introduction of second-generation androgen receptor antagonists (SG-ARAs) has
greatly impacted the treatment of metastatic prostate cancer, providing tolerable and …

Prostate cancer is heterogeneous and patients would benefit from methods that stratify those
who are likely to respond to systemic therapy. Here, we employ single-cell assays for …

The development of targeted therapies has revolutionized cancer treatment, offering
improved efficacy with reduced side effects compared with traditional chemotherapy. This …

Prostate cancer (PCa) is the most common cancer in men. The androgen receptor (AR) has
a pivotal role in the pathogenesis and progression of PCa. Many therapies targeting AR …

Our understanding of neuroendocrine prostate cancer (NEPC) has assumed a new
perspective in light of the recent advances in research. Although classical NEPC is rarely …